Table 2. Incidence and Severity of PONV and Antiemetics Use in the Dexamethasone Plus Hyper-hydration Group (Group DF) and Dexamethasone Group (Group D).
| PONV outcome | Group DF (n = 50) | Group D (n = 50) | P value |
|---|---|---|---|
| Incidence of PONV (0–24 h) | 11 (22%) | 22 (44%) | 0.03 |
| Nausea | 7 (14%) | 14 (28%) | 0.14 |
| Retching | 2 (4%) | 4 (8%) | 0.68 |
| Vomiting | 2 (4%) | 4 (8%) | 0.68 |
| VDS score (0–24 h) | |||
| 0 | 39 (78%) | 28 (56%) | 0.03 |
| 1 | 5 (10%) | 8 (16%) | 0.55 |
| 2 | 4 (8%) | 9 (18%) | 0.23 |
| 3 | 2 (4%) | 5 (10%) | 0.44 |
| Patients requiring antiemetics (VDS scores 2 and 3) | 6 (12%) | 14 (28%) | 0.79 |
| Total ondansetron dose (mg) during the first 24 h postoperatively | 0.83 (0.22) | 1.42 (0.39) | <0.001 |
Data are shown as numbers (%) or mean (SD). PONV: postoperative nausea and vomiting, VDS: verbal descriptive scale. P < 0.05 was considered significant.